Tardive movement disorders: A practical approach

Practical Neurology

Volumn 11, Issue 6, 2011, Pages 341-348

  Saifee, Tabish A ^a   Edwards, Mark J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; MOTOR DYSFUNCTION; REVIEW;

HUMANS; MOVEMENT DISORDERS;

EID: 81555201912     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1136/practneurol-2011-000077     Document Type: Review

References (30)

1. Robottom BJ, Weiner WJ, Factor SA. Movement disorders emergencies. Part 1: Hypokinetic disorders. Arch Neurol 2011;68:567-72.
2. Factor SA, Lang, AE, Weiner WJ. Drug induced movement disorders, 2nd Edn. Blackwell Futura, Malden, Massachusetts. 2005:371-441.
3. Kiriakakis V, Bhatia K P, Quinn N P, et al. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998;121 (Pt 11):2053-66.
4. Kenney C, Hunter C, Davidson A, et al. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 2008;48:379-84.
5. Schonecker M. [Paroxysmal dyskinesia as the effect of megaphen]. Nervenarzt 1957;28:550-3.
6. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 2005;50:541-7.
7. Thelma B, Srivastava V, Tiwari AK. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 2008;9:1285-306.
8. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004;65(Suppl 9):16-20.
9. Caroff SN, Hurford I, Lybrand J, et al. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin 2011;29:127-48, viii.
10. Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord 2009;24:2309-15.
11. Fenton WS, Blyler CR, Wyatt RJ, et al. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry 1997;171:265-8.
12. Burke RE, Kang UJ, Jankovic J, et al. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989;4:157-75.
13. Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 1993;43:937-41.
14. Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J 2011;87:132-41.
15. Madhusoodanan S, Alexeenko L, Sanders R, et al. Extrapyramidal symptoms associated with antidepressants-a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 2010;22:148-56.
16. Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother 2010;10:893-901.
17. Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;11:CD006633.
18. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279-81.
19. Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990;147:445-51.
20. Ludatscher JI. Stable remission of tardive dyskinesia by L-dopa. J Clin Psychopharmacol 1989;9:39-41.
21. Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 2010;33:271-5.
22. Woods SW, Saksa JR, Baker CB, et al. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2008;69:546-54.
23. Alabed S, Latifeh Y, Mohammad HA, et al. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2011;4:CD000203.
24. Kojima T, Yamauchi T, Miyasaka M, et al. Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study. Psychiatry Res 1992;43:129-36.
25. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2011;2:CD000209.
26. Brashear A, Ambrosius WT, Eckert GJ, et al. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 1998;13:158-61.
27. Dressler D, Oeljeschläger RO, Rüther E. Severe tardive dystonia: treatment with continuous intrathecal baclofen administration. Mov Disord 1997;12:585-7.
28. Miller CH, Fleischhacker W W. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000;22:73-81.
29. Andrews C, Aviles-Olmos I, Hariz M, et al. Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. J Neurol Neurosurg Psychiatry 2010;81:1383-9.
30. Lane RD, Glazer WM, Hansen TE, et al. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis 1985;173:353-7.